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Summary 
       The aim of this study was to reveal whether three biomarkers (p16, ProEx C, 
and HPV DNA) are useful in the diagnosis of cervical intraepithelial neoplasia and 
whether they could predict disease progression of cervical intraepithelial neoplasia-1. 
We analyzed 252 cervical specimens: non-dysplastic mucosa (n=9), cervical 
intraepithelial neoplasia (n=229), and squamous cell carcinoma (n=14). Immunostaining 
for p16 and ProEx C, and the hybridcapture II assay for HPV DNA were performed. 
Expression of p16 and staining for ProEx C were significantly higher in intraepithelial 
neoplasia-2/3 (96% to 100%) than in non-dysplastic mucosa (11%) or intraepithelial 
neoplasia-1 (40% to 53%). HPV DNA was detected in 69% of intraepithelial 
neoplasia-1, 95% of intraepithelial neoplasia-2, and 100% of intraepithelial neoplasia-3. 
Of 99 patients with intraepithelial neoplasia-1 for whom follow-up data was available, 
62 (73%) showed spontaneous regression, 17 (20%) demonstrated persistent low-grade 
lesion, and 7 (7%) progressed to intraepithelial neoplasia-2/3. Expressions of p16 and 
staining with ProEx C were significantly higher in the progression group than in the 
regression group. Testing for p16 and ProEx C were sensitive (86%) and moderately 
specific (60% and 61%, respectively) in predicting the progression of cervical 
intraepithelial neoplasia-1. HPV DNA testing was highly sensitive (100%) but less 
specific (37%). In conclusion, this study revealed that p16 and ProEx C are useful 
biomarkers for the diagnosis of cervical intraepithelial neoplasia, and have potential as 
predictors of progression of low-grade lesions. 
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1. Introduction 
 It is well established that most cervical cancers develop from non-invasive 
dysplastic lesions known as cervical intraepithelial neoplasia (CIN) [1,2]. There are 
three categories of CIN (CIN-1, -2, and -3) based on the degree of dysplasia [3], and 
infection with human papilloma viruses (HPV) is closely involved in the development 
and progression of these lesions [4]. Most developed countries have national or public 
screening systems to detect cervical dysplastic lesions at an early stage by cytology or 
HPV testing [5]. Precise diagnosis and prediction of progression risk are important 
issues in the clinical management of patients with CIN.  
 Histology is the gold standard in the diagnosis of CIN. However, the small size 
of biopsy specimens, potential sampling error, and heterogeneous distribution of 
dysplastic lesions can result in over- and under-diagnosis. Another difficulty is the 
existence of several CIN mimics such as immature squamous metaplasia [6,7]. Several 
biomarkers suitable for use on paraffin sections have been established to avoid these 
diagnostic inaccuracies. The protein p16INK4a (p16) is a cyclin-dependent kinase 
inhibitor which down-regulates progression through the G1-S transition checkpoint  
of the cell cycle [8]. Immunostaining for p16 has revealed overexpression in cervical 
squamous epithelium infected with high-risk HPV [9,10]. Two newer biomarkers 
include the minichromosome maintenance protein 2 (MCM2) and DNA topoisomerase 
II (TOP2A ) [11], both of which are involved in DNA replication in the S phase of the 
cell cycle. ProEx C is a cocktail of two monoclonal antibodies that targets the 
expression of these two proteins [12]. 
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 CIN2 and CIN3 have a considerable risk of progression to invasive cancer and 
are therefore usually treated by conization or other less invasive procedures. In contrast, 
approximately 80% of CIN1 lesions regress spontaneously [13], but they must be 
periodically followed up by cytology and biopsy to detect progression to higher grade 
lesions. At the moment, there is no consensus regarding the natural history of CIN1. 
Nonetheless, it seems important, not only for patient care but also from the viewpoint of 
medical economics, to establish a triage strategy for patients with CIN1.  
 In this study, we examined expressions of biomarkers in cervical premalignant 
lesions to determine which markers were useful in diagnosis and which could help in 
predicting the progression risk of CIN1.  
 
2. Patients and Methods 
2.1.  Patients 
       A total of 252 cervical specimens, consisting of biopsy (n=205), conization 
(n=34), and hysterectomy (n=13), were retrieved from the histopathology file of 
Kanazawa University Hospital, from 2005 to 2008. They consisted of non-dysplastic 
mucosa (n=9), CIN1 (n=123), CIN2 (n=57), CIN3 (n=49), and invasive squamous cell 
carcinoma (n=14). Type of specimens and mean age of patients in each diagnostic 
category are shown in Table 1. Before starting this study, all cases were independently 
reviewed by two authors (S.O. and Y.Z.). When there were disagreements about 
classification, a consensus diagnosis was made through discussion with a multi-header 
microscope. 
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2.2.  Immunohistochemistry 
       We performed p16 and ProEx C immunostaining using one representative 
section selected from each case using the EnVision+ system (Dako Cytomation, 
Glostrup, Denmark). The deparaffinized sections were microwaved twice in 
ethylenediaminetetraacetic acid (EDTA) buffer, pH 9.0, for 5 minutes at a 2-minute 
interval. After the blocking of endogenous peroxidase with REAL Peroxidase-Blocking 
Solution (Dako Cytomation), the deparaffinized sections were incubated for one hour at 
room temperature with primary monoclonal antibodies: anti-p16 (Dako Cytomation; 
clone E6H4; dilution 1:25) and ProEx C (BD, Franklin Lakes, NJ, USA; MCM2 clone 
26H16.19 and 27C5.6; TOP2A clone SWT3D1; ready to use). The sections were then 
incubated at room temperature for 1 hour with goat anti-mouse immunoglobulins 
conjugated to peroxidase labeled-dextran polymer (EnVision+; Dako Cytomation). The 
reaction products were developed by immersing the section in a 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) solution. Nuclei were lightly counterstained with 
hematoxylin.  
       The expression of p16 was evaluated as positive or negative according to the 
distribution of positive cells: positive, lower 1/4 of the epithelium or more; negative, 
less than lower 1/4. ProEx C staining was also assessed as positive (lower 3/4 of the 
epithelium or more) or negative (less than lower 3/4). Presence or absence of ProEx C 
staining in the basal layer was also recorded in each case. Expressions of ProEx C in 
basal and non-basal layer were separately examined. Positive basal staining meant the 
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expression in the basal layer with or without non-basal layer staining. Similarly, cases 
with basal positive / non-basal positive or basal negative / non-basal positive were 
determined as positive for non-basal staining. If staining was patchy rather than a 
complete band, the highest position of strong evident staining was evaluated based on 
the classification described above. Focal weak ambiguous staining was not considered.  
 
2.3.  HPV DNA testing 
 The hybridcapture II (HCII) assay for HPV DNA testing was performed with 
brushed sample taken just before the biopsy (biopsy cases) or at the time of cytology 
(surgical cases). The assay was performed using a HPV DNA HCII kit (Mitsubishi 
Chemical Medience, Tokyo, Japan), which is suitable for the detection of HPV types 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 (all medium or high risk subtypes for 
cervical cancer). HPV subtypes cannot be specified in this test. This assay was 
performed only for CIN and carcinoma cases.  
 
2.4.  Follow-up study 
 Follow-up data of the patients with CIN1 were retrospectively examined. Of 
123 patients, 5 (4%) underwent conization. After the diagnosis of CIN1, 19 patients 
(27%) did not undergo cytologic examination or biopsy at our hospital. The remaining 
99 patients enrolled in the follow-up study. All follow-up samples including biopsy, 
cytology, and surgical specimens were reviewed. The starting point was defined as the 
day that CIN1 was diagnosed in a biopsy, and outcome at the most recent examination 
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was classified into 3 groups as follows: (1) regression, never diagnosed as CIN2/3 and 
no dysplastic lesion at the most recent examination; (2) persistent CIN1, never 
diagnosed as CIN2/3 and remaining as CIN1 on biopsy or low-grade squamous 
intraepithelial lesion (LSIL) on cytology at the most recent examination; (3) progression 
to CIN2/3, diagnosed as CIN2/3 on biopsy or high-grade squamous intraepithelial 
lesion (HSIL) on cytology at least once. In our hospital, a fixed interval for follow up is 
6 months, but patients were followed in less than 3 months if there were concerns in 
colposcopic examination.  
 
2.5.  Statistical analysis 
 Statistical analyses were performed using the Mann-Whitney U or chi-square 
test for two groups or Tukey’s test for more than two groups. Correlations among 
different biomarker expressions were evaluated according to the concordance rate (%). 





The results of immunohistochemistry are summarized in Table 2. The 
expression of p16 was seen in one of 9 cases (11%) of non-dysplastic mucosa, and in 54 
of 123 cases (44%) of CIN1. Of note was that all but one case of CIN2/3 or carcinoma 
expressed p16 (Fig. 1). Expression of p16 in CIN2/3 and carcinoma was significantly 
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more frequent than in non-dysplastic mucosa and CIN1 (p<0.001). CIN1 also expressed 
p16 more frequently than did non-dysplastic mucosa (p=0.037).  
 
3.1.2. ProExC 
Positive staining for ProEx C was seen in only one case of non-dysplastic 
mucosa and in 40% of CIN1. Similarly to p16, ProEx C staining was commonly 
detected in high-grade lesions, and was almost consistent in CIN2/3 and carcinoma 
(96% to 100%) (Fig. 2A, B). Interestingly, ProEx C staining in the basal layer was also 
characteristic for high-grade lesions (Fig. 2C, D); it was noted in all but one case of 
CIN2/3 and carcinoma, 65 of 123 cases (53%) of CIN1, and only one case (11%) of 
non-dysplastic mucosa. ProEx C staining in either the basal or non-basal layer was 
noted significantly more frequently in CIN2/3 and carcinoma than in non-dysplastic 
mucosa and CIN1 (Table 2).  
 
3.2.  HPV testing 
 HCII for HPV was positive in 82 of 119 cases (69%) of CIN1. Positive results 
were more commonly obtained for CIN2 (95%) and CIN3 (100%) than for CIN1 (both 
p<0.001). All cases of carcinoma were also positive for HPV. 
  
3.3.  Correlations among the three biomarkers 
 As shown in Table 3, the results of immunohistochemistry for p16 and ProEx C 
were closely correlated with concordance rates of 84% to 87%. The agreement between 
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HCII and immunohistochemistry was poorer with concordance rates of 70% or less. 
Forty eight of 123 cases (39%) of CIN1 were positive for both basal ProEx C staining 
and HCII.  
 
3.4.  Follow-up study 
 Of 99 patients with CIN1 for whom follow-up data was available (follow-up 
period: range, 42 to 1781 days; median, 511 days), 76 (77%) showed spontaneous 
regression as evidenced by negative cytology or histology. Among them, 46 (46%) and 
27 (27%) patients were persistently negative for more than 1 and 2 years, respectively. 
Sixteen (16%) patients showed persistent CIN1, and 7 (7%) were found to have 
histological or cytological progression to CIN2/3. None of the patients with CIN1 in 
this study progressed to invasive squamous cell carcinoma during the follow-up period. 
 As shown in Table 4, expression of p16 and staining for ProEx C (non-basal 
and basal) were significantly higher in the progression group than in the regression 
group. The predictive value of each biomarker is shown in Table 5. Among patients with 
p16 expression, 6 (14%) showed histological progression, whereas the progression rate 
was only 2% in the negative cases (p=0.019). Similarly, patients with ProEx C (both 
non-basal and basal) staining showed significantly higher progression rate than negative 
cases (both p=0.016). The staining of p16 or ProEx C (non-basal) was highly sensitive 
(86%) and moderately specific (60% or 61%, respectively) to predict disease 
progression. ProEx C staining (basal) and HCII were highly sensitive (100%), but their 
specificity was less than 50%. Multiple biomarker positivity (both p16/ProEx C [basal], 
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both p16/ProEx C [non-basal], both ProEx C [basal]/ProEx C [non-basal], and all three 
markers) showed 86% sensitivity and 61 to 68% specificity.  
 
4. Discussion 
 The present study can be summarized as follows: (1) Immunostaining for p16 
and ProEx C was almost consistently positive in CIN2 and CIN3. (2) Staining for ProEx 
C at the basal layer was also characteristic for CIN2/3. (3) p16 and ProEx C were 
potential biomarkers to predict the progression of CIN1. (4) HPV testing was less 
specific for the progression risk of CIN1.  
 Like previous reports [14-19], our study confirmed the diagnostic utility of p16 
and ProEx C immunostaining for CIN. These tests are especially useful to distinguish 
between non-dysplastic epithelium and CIN. However, given the high positive rate even 
in CIN1, they seem less helpful for differentiation between CIN1 and CIN2/3. Another 
important issue is the expression of these markers in CIN mimics. Immature squamous 
metaplasia was not examined in this study, but Pinto et al. presented two cases of 
diagnostically problematic immature metaplasia, both of which were negative on ProEx 
C staining [15]. Larger studies with many cases of CIN mimics seem necessary to 
conclude this issue. 
 There is no consensus on how to evaluate ProEx C staining. Some groups 
consider the cases with staining of lower 1/3 of the epithelium or more as positive [19], 
whereas others use a threshold of 1/2 of the epithelial layer [17]. Evaluation is not easy, 
particularly when positive staining is seen in approximately the lower 1/3 to 1/2 of the 
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epithelium, which can commonly happen in CIN1. In our experience, ProEx C staining 
is easier to assess in the basal layer. We therefore suggest that staining in the basal layer 
might be helpful for the evaluation of borderline cases. The biological nature of 
MCM2/TOP2A expression detectable by ProEx C staining in the basal layer is unknown. 
Considering the cancer stem cell theory [20,21], the following theory may be reasonable. 
In the non-dysplastic cervical mucosa, MCM2 and TOP2A are not usually expressed in 
the basal layer, suggesting that stem cells in this layer are stable. In contrast, the basal 
expression of MCM2 and TOP2A may indicate activation or neoplastic transformation 
of stem cells. Among the 99 CIN 1 with follow-up, 7 (7%) showed ProEx C (basal) 
positivity and disease progression. 
 The issue of how to predict the progression of CIN1 is critical. Patients with 
CIN1 must be periodically followed up because they are at risk of progression to higher 
grade lesions or squamous cell carcinoma. However, it should be noted that 70% to 80% 
of low grade lesions regress spontaneously [13]. Hence alternative less expensive and 
equally effective management strategies could yield enormous cost savings and reduce 
patient anxiety. A large clinical trial was performed in the USA to assess whether or not 
HPV DNA testing is useful as a triage strategy for patients with LSIL/CIN1 [22]. That 
study concluded that HPV DNA testing has a limited potential for the clinical 
management of patients with LSIL because a very high percentage of women with this 
lesion were positive for HPV DNA [22]. The present study provided the interesting data 
that p16 and ProEx C could be potential markers to predict progression of CIN1. If 
CIN1 expressing these biomarkers had a higher progression risk, we could change the 
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follow-up strategy of CIN1 patients based on the results of these biomarkers.  
 In conclusion, this study revealed that p16 and ProEx C are useful biomarkers 
for the diagnosis of CIN, and have potential as predictive factors for progression risk of 
CIN1. 
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Figure legends 
Figure 1. Diffuse expression of p16 in a case of CIN3. p16 immunostaining, ×200. 
 
Figure 2. ProEx C expression (A) in lower 1/2 of squamous epithelium in a case of CIN 
2; (B) in almost the full thickness in a case of CIN2; (C) in the basal layer in a case of 
CIN2; (D) not observed in the basal layer in a case of non-dysplastic epithelium. ProEx 
C immunostaining, ×200 (A, B) and ×400 (C, D). 
Table 1 
 
Table 1. The number of cases, average age (years), and type of specimen (biopsy, 
conization, and hysterectomy) used in this study. 





Non-dysplastic mucosa 9 47 8/1 
CIN1 123 39 119/4 
CIN2 57 36 45/12 
CIN3 49 40 19/30 




Table 2. The results of biomarker expression.  
  Non-dysplastic
CIN1 CIN2 CIN3 
Squamous cell 
mucosa carcinoma 
  (n=9) (n=123) (n=57) (n=49) (n=14) 
p16 1 (11%) 54 (44%)* 56 (98%)*† 49 (100%)*† 14 (100%)*† 
ProEx C (non-basal)‡ 1 (11%) 49 (40%) 55 (96%)*† 49 (100%)*† 14 (100%)*† 
ProEx C (basal) 1 (11%) 65 (53%)* 56 (98%)*† 49 (100%)*† 14 (100%)*† 
HCII NA 82 (69%) 53 (95%)† 49 (100%)† 14 (100%) 
NA, not analyzed; *, p<0.05 vs. non-dysplastic mucosa; †, p<0.05 vs. CIN1;. ‡, including basal negative / 




Table 3. Correlation of different biomarker expression. These data includes all 
cases irrespective of morphologic diagnosis. 
  p16 ProEx C (non-basal)* ProEx C (basal)† 
p16       
ProEx C (non-basal)* 87% 
ProEx C (basal)† 84% 86% 
HCII 63% 66% 70% 
*, including basal negative / non-basal positive and both positive; †, including basal 




Table 4. Biomarker expression and follow-up of CIN 1 (n=99). 




Progression 7 6 (86%) 6 (86%) 7 (100%) 7 (100%) 
Persistent 16 11 (69%) 11 (69%) 11 (69%) 16 (100%) 
Regression 76 26 (34%)* 25 (33%)* 37 (49%)* 43 (57%) 
Regression (>1 year†) 46 19 (41%) 16 (35%)* 25 (54%) 29 (63%) 
Regression (>2 years†) 27 8 (30%)* 10 (37%) 13 (48%) 17 (63%) 
*, p<0.05 vs. the progression group; †, follow-up periods; ‡, including basal negative / non-basal positive and 
both positive; , including basal positive / non-basal negative and both positive.  
Table 5 
 
Table 5. Progression predictive values of biomarkers for CIN1 patients.  
  
Result n Progression rate 
Progression predictive value 
  Sensitivity Specificity 
p16 (+) 43 6 (14%) 86% 60% 
() 56 1 (2%) 
ProEx C (non-basal)* (+) 42 6 (14%) 86% 61% 
() 57 1 (2%) 
ProEx C (basal)† (+) 56 7 (13%) 100% 47% 
() 43 0 
HCII (+) 65 7 (11%) 100% 37% 
  () 34 0     
*, including basal negative / non-basal positive and both positive; †, including basal positive / non-basal 
negative and both positive.  
Figure 1
Figure 2
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